

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/718,596	11/24/2003	Dror Harats	27041	1012
7590 03/02/2006			EXAMINER	
Martin D. Moynihan			SHIAO, REI TSANG	
PRTSI, Inc. P.O. Box 16446			ART UNIT	PAPER NUMBER
Arlington, VA 22215			1626	

DATE MAILED: 03/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)				
	10/718,596	HARATS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Robert Shiao	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on <u>responses filed on 12/15/2005</u> .						
2a)⊠ This action is FINAL . 2b)☐ This						
3) Since this application is in condition for alloward	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-27 is/are pending in the application.						
4a) Of the above claim(s) <u>9-19</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-8 and 27</u> is/are rejected.						
7) Claim(s) <u>20-26</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)⊠ The drawing(s) filed on <u>24 November 2003</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	nent Application (PTO-152)				

Application/Control Number: 10/718,596 Page 2

Art Unit: 1626

DETAILED ACTION

1. This application claims benefit of the provisional application: 60/252,574 with a filing date 11/24, 2000.

2. Amendment of claims 1 and 8, and addition of claims 20-27 in the amendment filed on December 15, 2005, is acknowledged. Claims 1-27 are pending in the application. Since the newly added claims 20-27 are commensurate with the scope of the invention, therefore, claims 1-27 are prosecuted in the case.

Responses to Amendment/Arguments

- 3. Rejection of claims 1-8 under 35 U.S.C. 112, first paragraph, has been overcome in part in the amendment filed on December 15, 2005. Rejection of claims 1-8 under 35 U.S.C. 112, first paragraph, is maintained. Elimination of limitation "anti-inflammatory compounds", "analgesics", "growth factors", "toxins", or "tolerizing antigens", would obviate the rejection, see claim 8, lines 4-5, or claim 27, lines 4-5. Claim 27 also is rejected under 35 U.S.C. 112, first paragraph, as the same reasons of claim 1.
- 4. Applicant's arguments regarding rejection of claims claims 1-8 under 35 U.S.C. 102(b) or 103(a) filed on December 15, 2005 have been fully considered and they are persuasive. Methods of use of the instant compounds, i.e., dose or administration, etc., have not been disclosed in the prior art, i.e., Small et al. publication, Molecular Immunology (1989), 26(8), 711-19. Therefore, rejection of claims 1-8 under 35 U.S.C. 102(b) or 103(a), has been withdrawn.

Application/Control Number: 10/718,596 Page 3

Art Unit: 1626

Claim Objections

5. Claims 9-19 are objected to as being non-elected invention. Elimination of claims 9-19 would obviate the objection.

- 6. Claims 20-26 are objected to as not consistence with the scope of claim 1. Elimination of the term "cardiovascular disease" would obviate the objection, see claim 20, lines 1-2.
- 7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM.

Art Unit: 1626

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KAMAL A. SAEED, PH.D. PRIMARY EXAMINER

Joseph K. McKane

Supervisory Patent Examiner

Art Unit 1626

Robert Shiao, Ph.D. Patent Examiner Art Unit 1626

February 14, 2006